We are live on ! Find out more
DNLI icon

Denali Therapeutics
DNLI

230 hedge funds and large institutions have $1.93B invested in Denali Therapeutics in 2025 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 84 increasing their positions, 64 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

230% more call options, than puts

Call options by funds: $2.08M | Put options by funds: $630K

31% more repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 64

25% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 36

4% more funds holding

Funds holding: 222 → 230 (+8)

1.11% more ownership

Funds ownership: 93.6% → 94.71% (+1.1%)

4% more capital invested

Capital invested by funds: $1.85B → $1.93B (+$76.1M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
230
Holders Change
+8
Holders Change %
+3.6%
% of All Funds
3.03%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
45
Increased
84
Reduced
64
Closed
36
Calls
$2.08M
Puts
$630K
Net Calls
+$1.45M
Net Calls Change
+$1.11M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$45.7M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$31.2M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$31.2M
4
Norges Bank
Norges Bank
Norway
+$12.7M
5
MCM
Masters Capital Management
Georgia
+$8.45M

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$80.9M
2
BlackRock
BlackRock
New York
-$25.1M
3
CCM
Camber Capital Management
Massachusetts
-$12M
4
Marshall Wace
Marshall Wace
United Kingdom
-$11M
5
Squarepoint
Squarepoint
New York
-$9.34M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$14.8M +$649K +46,123 +5%
UBS Group
27
UBS Group
Switzerland
$13.3M +$2.28M +162,335 +21%
Aberdeen Group
28
Aberdeen Group
United Kingdom
$12.6M +$2.01M +142,936 +19%
Millennium Management
29
Millennium Management
New York
$12.6M -$8.34M -592,567 -40%
CC
30
Casdin Capital
New York
$12.5M -$1.41M -100,000 -10%
CS
31
Candriam SCA
Luxembourg
$11.8M -$196K -13,913 -2%
SL
32
Siren LLC
Connecticut
$11.5M – – –
Bank of New York Mellon
33
Bank of New York Mellon
New York
$11.1M -$4.41M -313,136 -28%
Voloridge Investment Management
34
Voloridge Investment Management
Florida
$10.8M +$6.59M +468,554 +155%
SC
35
Stempoint Capital
New York
$9.9M +$575K +40,837 +6%
Bank of America
36
Bank of America
North Carolina
$9.1M +$2.85M +202,465 +45%
CM
37
Cercano Management
Washington
$8.74M – – –
MCM
38
Masters Capital Management
Georgia
$8.39M +$8.45M +600,000 New
N
39
Nuveen
North Carolina
$8.33M +$3.83M +272,272 +84%
SBH
40
Segall Bryant & Hamill
Illinois
$7M +$3.09M +219,420 +78%
TD Asset Management
41
TD Asset Management
Ontario, Canada
$6.94M +$2.64M +187,710 +61%
Ensign Peak Advisors
42
Ensign Peak Advisors
Utah
$6.63M -$1.61M -114,090 -19%
YCM
43
Yiheng Capital Management
California
$6.58M – – –
Barclays
44
Barclays
United Kingdom
$5.96M +$2.61M +185,333 +77%
Pictet Asset Management
45
Pictet Asset Management
Switzerland
$5.85M +$1M +71,153 +21%
Holocene Advisors
46
Holocene Advisors
New York
$5.64M +$5.67M +403,172 New
CCM
47
Camber Capital Management
Massachusetts
$5.6M -$12M -850,000 -68%
CSS
48
Cubist Systematic Strategies
Connecticut
$5.55M +$5.58M +396,586 New
Royal Bank of Canada
49
Royal Bank of Canada
Ontario, Canada
$5.46M +$5.29M +375,719 +2,603%
Schroder Investment Management Group
50
Schroder Investment Management Group
United Kingdom
$5.41M +$1.33M +94,744 +32%
1
2
3 4 5

DNLI Hedge Fund Activity: Q2 2025 in Review

230 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q2 2025, worth a combined $1.93B — up 4.1% from $1.85B a quarter earlier.

Buyers outnumbered sellers: 45 funds opened new DNLI positions and 36 closed out — a net gain of 9 holders — while 84 added to existing stakes and 64 trimmed.

The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $45.7M. The largest seller was Wellington Management Group, cutting an estimated $80.9M.

  • 230 institutional investors held Denali Therapeutics (DNLI) as of Q2 2025, up from 222 in Q1 2025.
  • Funds reported $1.93B of Denali Therapeutics stock for Q2 2025, up 4.1% quarter-over-quarter.
  • 45 funds opened new Denali Therapeutics positions in Q2 2025 and 36 closed out, a net change of +9 holders.
  • The largest Denali Therapeutics buyer in Q2 2025 was T. Rowe Price Investment Management, an estimated $45.7M added.
  • The largest Denali Therapeutics seller in Q2 2025 was Wellington Management Group, an estimated $80.9M sold.

Based on aggregated 13F filings for Q2 2025.